{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:41:53Z","timestamp":1790221313176,"version":"4.1.0"},"reference-count":22,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"6","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2014]]},"DOI":"10.2133\/dmpk.dmpk-14-rg-031","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T23:19:29Z","timestamp":1401751169000},"page":"449-454","source":"Crossref","is-referenced-by-count":39,"title":["Influence of UGT1A1 *6, *27, and *28 Polymorphisms on Nilotinib-induced Hyperbilirubinemia in Japanese Patients with Chronic Myeloid Leukemia"],"prefix":"10.2133","volume":"29","author":[{"given":"Maiko","family":"Abumiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Niioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatomo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0005","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a secondgeneration tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"DeRemer","year":"2008","journal-title":"Clin. Ther."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0010","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2009.08.031","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia","volume":"34","author":"Breccia","year":"2010","journal-title":"Leuk. Res."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0025","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0030","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0040","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","article-title":"Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib","volume":"14","author":"Hazarika","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0045","doi-asserted-by":"crossref","first-page":"17960","DOI":"10.1016\/S0021-9258(17)32403-1","article-title":"Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man","volume":"269","author":"Bosma","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(02)00359-8","article-title":"Inherited disorders of bilirubin metabolism","volume":"38","author":"Bosma","year":"2003","journal-title":"J. Hepatol."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0009-8981(97)00167-8","article-title":"Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias","volume":"266","author":"Clarke","year":"1997","journal-title":"Clin. Chim. Acta"},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","article-title":"The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome","volume":"333","author":"Bosma","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0065","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?","volume":"95","author":"Beutler","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0070","first-page":"6921","article-title":"Polymorphisms ofUDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis","volume":"60","author":"Ando","year":"2000","journal-title":"Cancer Res."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.tpj.6500335","article-title":"Haplotype structures of the UGT1A gene complex in a Japanese population","volume":"6","author":"Saeki","year":"2006","journal-title":"Pharmacogenomics J."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0080","first-page":"923","article-title":"Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent","volume":"2","author":"Fukui","year":"2011","journal-title":"Oncol. Lett."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-010-1445-3","article-title":"The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1","volume":"67","author":"Fujita","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0090","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","article-title":"UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia","volume":"21","author":"Singer","year":"2007","journal-title":"Leukemia"},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10147-013-0562-5","article-title":"Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia","volume":"19","author":"Shibata","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0100","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/bmc.1364","article-title":"High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma","volume":"24","author":"Miura","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0105","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.2133\/dmpk.DMPK-14-RG-031_bb0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00228-012-1385-4","article-title":"Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia","volume":"69","author":"Giles","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715303645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715303645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T16:11:00Z","timestamp":1649175060000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715303645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"alternative-id":["S1347436715303645"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-14-rg-031","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}